CAMBRIDGE, Mass. — Parabilis Medicines appointed biopharmaceutical finance executive Alan M. Sebulsky to its board of directors, adding a veteran public markets investor with decades of experience evaluating biotech companies and drug development portfolios.
Parabilis is a clinical-stage biopharmaceutical company developing medicines through its Helicon peptide platform, which is designed to target disease biology that has historically been difficult to drug.
“We are very pleased to welcome Alan to the Parabilis Board of Directors,” said Mathai Mammen, M.D., Ph.D., chairman, CEO and president of Parabilis Medicines. “Alan brings a rare perspective developed over decades as both a leading biopharmaceutical equity analyst and a seasoned public markets investor. He has deep experience evaluating scientific opportunities, capital allocation, portfolio strategy and the drivers of durable company value.”
Sebulsky has more than four decades of experience in the biopharmaceutical industry, including public company investment, financial strategy, portfolio evaluation and board leadership. He most recently served as partner and portfolio manager at Adage Capital Management, where he led a team overseeing a diversified biopharmaceutical portfolio with more than $2 billion in assets.
He previously founded Apothecary Capital, an asset management firm focused on healthcare and biopharmaceutical investments.
Sebulsky has also served on the boards and audit committees of Jazz Pharmaceuticals and Arrow International, both publicly traded healthcare companies, as well as on the boards of three private healthcare companies backed by Apothecary Capital. In those roles, he worked with company leadership on portfolio, commercial and business strategy.
He holds an M.S. in finance and a B.B.A. in finance and economics from the University of Wisconsin–Madison.
